Pantoprazole 40mg + Itopride 150mg
Pantoprazole 40mg (same irreversible H⁺/K⁺-ATPase proton pump inhibitor mechanism as PANSWING™ LS) + Itopride 150mg (dual mechanism prokinetic: D2 receptor antagonism + acetylcholinesterase inhibition). Unlike levosulpiride which is purely a D2 antagonist, itopride provides prokinetic activity through two complementary pathways — blocking dopaminergic inhibition of GI motility AND preventing breakdown of endogenous acetylcholine by inhibiting acetylcholinesterase. This dual prokinetic mechanism provides more potent gastric emptying acceleration and more complete restoration of antroduodenal coordination compared to single-mechanism prokinetics.
Functional dyspepsia with prominent post-prandial distress, GORD with delayed gastric emptying, non-ulcer dyspepsia, nausea and bloating from gastroparesis. Itopride's dual prokinetic mechanism makes PANSWING™ IT preferred over PANSWING™ LS when more potent prokinetic action is clinically required — for example in diabetic gastroparesis, post-vagotomy gastric stasis, or severe functional dyspepsia with marked delayed gastric emptying.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
PANSWING™ IT sits at the premium end of the PANSWING™ prokinetic-PPI range, offering more potent prokinetic activity through itopride's dual mechanism for cases where PANSWING™ LS provides insufficient gastric emptying acceleration. For gastroenterologists managing diabetic gastroparesis or severe functional dyspepsia, having both levosulpiride and itopride combinations under the same brand enables stepwise escalation of prokinetic intensity within a familiar product family.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.